Publications
CuraCell study demonstrates long-term immune control achieved in prostate cancer
CuraCell is proud to announce the publication of its latest research article,“Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer,”in the peer-reviewed journal Frontiers in Oncology.
The study provides novel insights into how Tumor-Infiltrating Lymphocyte (TIL) therapy, when combined with PD-1 blockade, can drive durable immune responses and lasting clinical remission—even in prostate cancer, a tumor type historically resistant to immunotherapy.
In this longitudinal case study, a patient with treatment-refractory metastatic prostate cancer achieved complete and sustained tumor remission lasting over five years following multiple TIL infusions combined with anti–PD-1 therapy. Using high-throughput T-cell receptor (TCR) sequencing over a five-year period, researchers tracked the persistence and evolution of both infused and endogenous T-cell clonotypes, revealing long-term clonal persistence, robust immune reactivation, and the emergence of new tumor-reactive T-cell clones correlating with tumor regression.
“This work demonstrates the remarkable potential of combining TIL therapy with PD-1 blockade to overcome immune resistance in solid tumors,” said Lucas Arruda, CSO of CuraCell. “By achieving durable immune control in prostate cancer, we are expanding the boundaries of what TIL-based immunotherapy can accomplish.”
The full article, “Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer,” is published in Frontiers in Oncology and can be accessed here:
“These findings reinforce the importance of longitudinal immunogenomic monitoring in personalized cell therapy,” added Arruda. “They strengthen the scientific foundation for exploring combined adoptive T-cell transfer and checkpoint blockade strategies to extend clinical benefit in solid ‘cold’ tumors.”